Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit Therapeutics PLC “optimist for the future” after latest ridinilazole phase II trial data

Richard Pye, director of corporate communications at Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM), says he has been “really encouraged” by the data from the phase II trial for its new antibiotic for hospital superbug C.Diff.

Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.

The further positive data showed that ridinilazole can preserve the micobiome in the gut as it treats the condition.

“What is really gratifying is that what we’ve seen in the pre-clinical data is actually translating now into patients,” he says.

 
Meet Acal Plc and Scancell Holdings Plc at our event, London, 07 July 2016. Register here »
View full SUMM profile

Summit Therapeutics PLC Timeline

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.